IP Library › Granted Patent US 12,441,724
Granted Patent B2
US 12,441,724 · App. 17/724,753 · Granted Oct 14, 2025

Inhibitors of plasma kallikrein and uses thereof

Inventors: Nikolaos Papaioannou (Newton, MA); Sarah Jocelyn Fink (Arlington, MA); Thomas Allen Miller (Wakefield, MA); Gerald Wayne Shipps, Jr. (Stoneham, MA); Jeremy Mark Travins (Southborough, MA); David Edward Ehmann (Lexington, MA); Alastair Rae (Saffron Walden, GB); John Mark Ellard (Buntingford, GB)
Assignee: Takeda Pharmaceutical Company Limited
C07D471/04A61P9/00A61P29/00C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,441,724
App. No.
17/724,753
Granted
Oct 14, 2025
Kind
B2
Abstract

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Claims (99)

1. A method of treating hereditary angioedema comprising administering to a patient in need thereof a compound of Formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

Cy A is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur, 5- to 6-membered heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, and 7- to 10-membered bicyclic heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-4 R A groups;

each R A is independently selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

Cy B is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from oxygen, nitrogen, and sulfur, and 7- to 10-membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein Cy B is substituted with 0-5 R B groups;

each R B is independently selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

L is selected from -QC(R) 2 —, —C(R) 2 Q-, -QC(Q)-, —C(Q)Q-, —C(R) 2 QC(O)—, and —C(O)QC(R) 2 —, wherein each Q is independently a monovalent or divalent group as valency allows, selected from the group consisting of O, N(R), and (S);

R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen and C 1-6 aliphatic;

R 5 , R 6 , R 7 , R 8 , and R 9 are independently selected from hydrogen, halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur; and

each R is independently hydrogen, —CN, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

or two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form a ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, and sulfur, and 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur;

with the proviso that the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide.

2. The method of claim 1 , wherein the compound is of Formula (IV):

or a pharmaceutically acceptable salt thereof,

wherein:

Cy A is a 5-membered heteroarylene having 1-4 heteroatoms selected from oxygen and nitrogen, wherein Cy A is substituted with 0-3 R A groups;

L is selected from —NHC(O)— and —C(O)NH—;

R 6 , R 8 , and R 9 are independently selected from hydrogen, halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

R 7 is —F, —Cl, or —Br;

W 4 is carbon or nitrogen;

R 10 and R 11 are each optionally present, and if present are independently selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

R 13 is selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 2-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

R 14 is optionally present, and if present and is selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 3-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur; and

each R is independently hydrogen, —CN, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

or two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form a ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, and sulfur, and 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur.

3. The method of claim 1 , wherein the compound is of Formula (V):

or a pharmaceutically acceptable salt thereof,

wherein:

Cy A is a 5-membered heteroarylene having 1-4 nitrogens, wherein when Cy A comprises 3 nitrogens, Cy A is not

L is selected from —NHC(O)— and —C(O)NH—;

R 6 , R 8 , and R 9 are independently selected from hydrogen, halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

R 7 is —F, —Cl, or —Br;

R 10 is optionally present, and if present is selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

R 11 is optionally present, and if present is selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

R 13 is selected from —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- or 5-7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

R 14 is optionally present, and if present and is selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 3-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur; and

each R is independently hydrogen, —CN, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

or two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form a ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, and sulfur, and 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur.

4. The method of claim 1 , wherein L is selected from the group consisting of:

wherein # represents to point of attachment to Cy A .

5. The method of claim 1 , wherein the compound is of Formula (II):

or a pharmaceutically acceptable salt thereof,

wherein:

Cy A is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclylene having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur, 5- to 6-membered heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclylene having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, and 7- to 10-membered bicyclic heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-4 R A groups;

each R A is independently selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

Cy B is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from oxygen, nitrogen, and sulfur, and 7- to 10-membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein Cy B is substituted with 0-5 R B groups;

each R B is independently selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

R 1 and R 2 are independently selected from hydrogen and C 1-6 aliphatic;

R 6 and R 7 are independently selected from hydrogen, halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur; and

each R is independently hydrogen, —CN, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

or two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form a ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, and sulfur, and 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur;

with the proviso that the compound is other than N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)isonicotinamide.

6. The method of claim 1 , wherein Cy A is selected from 5- to 6-membered heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, and 7- to 10-membered bicyclic heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur wherein Cy A is substituted with 0-4 R A groups.

7. The method of claim 1 , wherein Cy A is a 5-membered heteroarylene having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-2 R A groups.

8. The method of claim 1 , wherein Cy A is selected from the group consisting of:

wherein * represents to point of attachment to L.

9. The method of claim 1 , wherein the compound is of Formula (III-a) through (III-d):

or a pharmaceutically acceptable salt thereof,

wherein:

each R A is independently selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

Cy B is selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-5 heteroatoms selected from oxygen, nitrogen, and sulfur, and 7- to 10-membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein Cy B is substituted with 0-5 R B groups;

each R B is independently selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

R 1 and R 2 are independently selected from hydrogen and C 1-6 aliphatic;

R 6 and R 7 are independently selected from hydrogen, halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur; and

each R is independently hydrogen, —CN, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

or two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form a ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, and sulfur, and 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur.

10. The method of claim 1 , wherein Cy B is a 7- to 10-membered bicyclic heteroaryl having 1-5 heteroatoms selected from oxygen, nitrogen, and sulfur, wherein Cy B is substituted with 0-5 R B groups.

11. The method of claim 1 , wherein Cy B is

wherein:

W 1 , W 2 , W 3 , and W 4 are independently selected from carbon and nitrogen;

R 10 , R 11 , R 12 , R 13 , and R 14 are each optionally present when attached to a carbon atom, and if present correspond to an occurrence of R B independently selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur; and

each R is independently hydrogen, —CN, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

or two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form a ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, and sulfur, and 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur.

12. The method of claim 1 , wherein Cy B is selected from the group consisting of:

13. The method of claim 1 , wherein Cy B is

wherein:

W 2 is selected from carbon, nitrogen, oxygen, and sulfur;

W 1 , W 3 , and W 4 are independently selected from carbon and nitrogen;

R 10 , R 11 , R 12 , R 13 , and R 14 are each optionally present when attached to a carbon atom, and if present correspond to an occurrence of R B independently selected from halogen, —CN, —C(R)═N(R), —C(O)R, —C(O) 2 R, —C(O)N(R) 2 , —NO 2 , —N(R)—N(R) 2 , —N(R) 2 , —N(R)C(O)R, —N(R)C(O) 2 R, —N(R)C(O)N(R) 2 , —N(R)S(O) 2 R, —OR, —OC(O)R, —OC(O)N(R) 2 , —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , —S(O) 2 N(R) 2 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur; and

each R is independently hydrogen, —CN, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, and sulfur;

or two R groups on the same carbon or nitrogen are taken together with their intervening atoms to form a ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic ring having 0-2 heteroatoms selected from oxygen, nitrogen, and sulfur, and 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur.

14. The method of claim 1 , wherein Cy B is selected from the group consisting of:

15. The method of claim 1 , wherein R 5 , R 6 , R 7 , R 8 , and R 9 are independently selected from hydrogen, halogen, —CN, —N(R) 2 , —OR, or an optionally substituted group selected from C 1-6 aliphatic, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, wherein each R is independently hydrogen or C 1-6 aliphatic.

16. The method of claim 1 , wherein R 6 is selected from hydrogen and halogen.

17. The method of claim 1 , wherein the compound is N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((3-chloroquinolin-6-yl)methyl)-1H-pyrazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

18. The method of claim 1 , wherein the compound is N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

19. The method of claim 1 , wherein the compound is N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-pyrazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

20. The method of claim 1 , wherein the compound is N-((7-bromoimidazo[1,5-a]pyridin-1-yl)methyl)-1-((7-chloro-6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

21. The method of claim 1 , wherein the compound is N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

22. The method of claim 1 , wherein the compound is N-((7-chloroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

23. The method of claim 1 , wherein the compound is N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-pyrazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

24. The method of claim 1 , wherein the compound is N-((7-bromo-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-b]pyridazin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

25. The method of claim 1 , wherein the compound is N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

26. The method of claim 1 , wherein the compound is N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6,7-dichloroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

27. The method of claim 1 , wherein the compound is N-((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)-1-((6-cyclopropylbenzofuran-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

28. The method of claim 1 , wherein the compound is 4-(((7-chloro-8-fluoroimidazo[1,5-a]pyridin-1-yl)methyl)carbamoyl)-1-((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-imidazole-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

29. The method of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: FINK, SARAH JOCELYN
To: BIODURO LLC
Reel/Frame 060979/0113 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: RAE, ALASTAIR; ELLARD, JOHN MARK
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 060979/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: PAPAIOANNOU, NIKOLAOS; MILLER, THOMAS ALLEN; SHIPPS, GERALD WAYNE, JR.; TRAVINS, JEREMY MARK; EHMANN, DAVID EDWARD
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 060979/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: BIODURO LLC
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 060979/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
To: CHARLES RIVER LABORATORIES, INC.
Reel/Frame 060979/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 060979/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: CHARLES RIVER LABORATORIES, INC.
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 060979/0360 →
Continuity (5)
Division 16908497 · Jun 22, 2020
Division 16299996 · Mar 12, 2019
Provisional Application 62757728 · Nov 8, 2018
Provisional Application 62642376 · Mar 13, 2018
Related Publication 20230078513A1 · Mar 16, 2023
References Cited (164)
US 4861760A · Mazuel et al. · 1989 [cited by applicant]
US 4911920A · Jani et al. · 1990 [cited by applicant]
US 5212162A · Missel et al. · 1993 [cited by applicant]
US 5403841A · Lang et al. · 1995 [cited by applicant]
US 7166596B2 · Yu et al. · 2007 [cited by applicant]
US 8153658B2 · Hachiya et al. · 2012 [cited by applicant]
US 10259803B2 · McDonald et al. · 2019 [cited by applicant]
US 10301284B2 · McDonald et al. · 2019 [cited by applicant]
US 10730874B2 · Papaioannou et al. · 2020 [cited by applicant]
US 11352356B2 · Papaioannou et al. · 2022 [cited by applicant]
US 11370803B2 · Papaioannou et al. · 2022 [cited by applicant]
US 11787796B2 · Papaioannou · 2023 [cited by examiner]
US 12065448B2 · Papaioannou et al. · 2024 [cited by applicant]
US 20080255025A1 · Ladner · 2008 [cited by applicant]
US 20100039029A1 · Yang et al. · 2010 [cited by applicant]
US 20100130563A1 · Sinha et al. · 2010 [cited by applicant]
US 20120264798A1 · Sinha et al. · 2012 [cited by applicant]
US 20140213611A1 · Evans et al. · 2014 [cited by applicant]
US 20160106102A1 · Kuebbeler et al. · 2016 [cited by applicant]
US 20160168123A1 · Edwards et al. · 2016 [cited by applicant]
US 20160200704A1 · Mcdonald et al. · 2016 [cited by applicant]
US 20170029406A1 · Mcdonald et al. · 2017 [cited by applicant]
US 20170305863A1 · Evans et al. · 2017 [cited by applicant]
US 20180155348A1 · Li et al. · 2018 [cited by applicant]
US 20180282328A1 · Chan et al. · 2018 [cited by applicant]
US 20180319782A1 · Davie et al. · 2018 [cited by applicant]
US 20190127366A1 · Mcdonald et al. · 2019 [cited by applicant]
US 20190169162A1 · Beaton et al. · 2019 [cited by applicant]
US 20190284182A1 · Papaioannou et al. · 2019 [cited by applicant]
US 20200239463A1 · Travins et al. · 2020 [cited by applicant]
US 20200317667A1 · Papaioannou et al. · 2020 [cited by applicant]
US 20210078999A1 · Papaioannou et al. · 2021 [cited by applicant]
US 20210079022A1 · Papaioannou et al. · 2021 [cited by applicant]
US 20220298176A1 · Papaioannou et al. · 2022 [cited by applicant]
US 20230391773A1 · Papaioannou et al. · 2023 [cited by applicant]
US 20240199612A1 · Papaioannou et al. · 2024 [cited by applicant]
US 20240199613A1 · Papaioannou et al. · 2024 [cited by applicant]
US 20240226106A1 · Papaioannou et al. · 2024 [cited by applicant]
US 20240228488A1 · Papaioannou et al. · 2024 [cited by applicant]
US 20240382482A1 · Papaioannou et al. · 2024 [cited by applicant]
CN 105777632A · 2016 [cited by applicant]
CN 105849109A · 2016 [cited by applicant]
CN 106061480A · 2016 [cited by applicant]
CN 107072985A · 2017 [cited by applicant]
CN 110022875A · 2019 [cited by applicant]
CN 111848599A · 2020 [cited by applicant]
CN 112135825A · 2020 [cited by applicant]
EP 1908471A1 · 2008 [cited by applicant]
EP 1908762A2 · 2008 [cited by applicant]
EP 1963329A2 · 2008 [cited by applicant]
JP S62181284A · 1987 [cited by applicant]
JP 2000256286A · 2000 [cited by applicant]
JP 2012111731A · 2012 [cited by applicant]
JP 2017520597A · 2017 [cited by applicant]
JP 2019529484A · 2019 [cited by applicant]
JP 2020529998A · 2020 [cited by applicant]
JP 2022549601A · 2022 [cited by applicant]
KR 1020170034902A · 2017 [cited by applicant]
WO WO9220350A1 · 1992 [cited by applicant]
WO WO9605309A2 · 1996 [cited by applicant]
WO WO9736876A1 · 1997 [cited by applicant]
WO WO0119829A2 · 2001 [cited by applicant]
WO WO0127107A2 · 2001 [cited by applicant]
WO WO0200651A2 · 2002 [cited by applicant]
WO WO0250065A2 · 2002 [cited by applicant]
WO WO2002051831A1 · 2002 [cited by applicant]
WO WO2005005443A1 · 2005 [cited by applicant]
WO WO2005115382A1 · 2005 [cited by applicant]
WO WO2006091898A2 · 2006 [cited by applicant]
WO WO2007009236A1 · 2007 [cited by applicant]
WO WO2007128460A1 · 2007 [cited by applicant]
WO WO2008059854A1 · 2008 [cited by applicant]
WO WO2008116665A1 · 2008 [cited by applicant]
WO WO2008154642A2 · 2008 [cited by applicant]
WO WO2009023179A2 · 2009 [cited by applicant]
WO WO2010065760A1 · 2010 [cited by applicant]
WO WO2010091409A1 · 2010 [cited by applicant]
WO WO2010124082A1 · 2010 [cited by applicant]
WO WO2010124086A1 · 2010 [cited by applicant]
WO WO2010124102A1 · 2010 [cited by applicant]
WO WO2010124108A1 · 2010 [cited by applicant]
WO WO2010124112A1 · 2010 [cited by applicant]
WO WO2010124114A1 · 2010 [cited by applicant]
WO WO2010124116A1 · 2010 [cited by applicant]
WO WO2010132598A1 · 2010 [cited by applicant]
WO WO2010137738A1 · 2010 [cited by applicant]
WO WO2011135303A2 · 2011 [cited by applicant]
WO WO2012016133A2 · 2012 [cited by applicant]
WO WO2012051036A1 · 2012 [cited by applicant]
WO WO2012051361A1 · 2012 [cited by applicant]
WO WO2012058645A1 · 2012 [cited by applicant]
WO WO2012082689A1 · 2012 [cited by applicant]
WO WO2012092471A2 · 2012 [cited by applicant]
WO WO2012116257A1 · 2012 [cited by applicant]
WO WO2012129562A2 · 2012 [cited by applicant]
WO WO2012139425A1 · 2012 [cited by applicant]
WO WO2013052526A1 · 2013 [cited by applicant]
WO WO2013081094A1 · 2013 [cited by applicant]
WO WO2013101974A1 · 2013 [cited by applicant]
WO WO2013127269A1 · 2013 [cited by applicant]
WO WO2014004376A2 · 2014 [cited by applicant]
WO WO2014187928A1 · 2014 [cited by applicant]
WO WO2015063093A1 · 2015 [cited by applicant]
WO WO2015095449A1 · 2015 [cited by applicant]
WO WO2015099196A1 · 2015 [cited by applicant]
WO WO2015103317A1 · 2015 [cited by applicant]
WO WO2015188051A1 · 2015 [cited by applicant]
WO WO2016011209A1 · 2016 [cited by applicant]
WO WO2016029146A1 · 2016 [cited by applicant]
WO WO2016083816A1 · 2016 [cited by applicant]
WO WO2016168059A1 · 2016 [cited by applicant]
WO WO2017001924A1 · 2017 [cited by applicant]
WO WO2017001926A2 · 2017 [cited by applicant]
WO WO2017001936A2 · 2017 [cited by applicant]
WO WO2017161028A1 · 2017 [cited by applicant]
WO WO2017207983A1 · 2017 [cited by applicant]
WO WO2017207985A1 · 2017 [cited by applicant]
WO WO2017208005A1 · 2017 [cited by applicant]
WO WO2018011628A1 · 2018 [cited by applicant]
WO WO2018015818A2 · 2018 [cited by applicant]
WO WO2018141002A2 · 2018 [cited by applicant]
WO WO2018161033A1 · 2018 [cited by applicant]
WO WO2018229543A2 · 2018 [cited by applicant]
WO WO2018234808A1 · 2018 [cited by applicant]
WO WO2019028362A1 · 2019 [cited by applicant]
WO WO2019106375A1 · 2019 [cited by applicant]
WO WO2019106377A1 · 2019 [cited by applicant]
WO WO2019178129A1 · 2019 [cited by applicant]
WO WO2021004535A1 · 2021 [cited by applicant]
WO WO2021055589A1 · 2021 [cited by applicant]
WO WO2021055621A1 · 2021 [cited by applicant]
WO WO2022197755A1 · 2022 [cited by applicant]
WO WO2022197756A1 · 2022 [cited by applicant]
WO WO2022197758A1 · 2022 [cited by applicant]
WO WO2022197763A1 · 2022 [cited by applicant]
WO WO2022197789A1 · 2022 [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1027012-72-1, 1 page, Jun. 10, 2008. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1212485-78-3, Mar. 21, 2010. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1252171-01-9, 1 page, Nov. 9, 2010. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1252171-06-4, 1 page, Nov. 9, 2010. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1281095-27-9, 1 page, Apr. 17, 2011. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1290603-18-7, 1 page, May 5, 2011. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1293616-34-8, 1 page, May 12, 2011. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1294658-40-4, 1 page, May 15, 2011. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1316344-05-4, 1 page, Aug. 12, 2011. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1318660-49-9, 1 page, Aug. 16, 2011. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1319066-26-6, 1 page, Aug. 17, 2011. [cited by applicant]
Chemical Abstracts Service, Database Accession No. 1347295-90-2, 1 page, Dec. 2, 2011. [cited by applicant]
Hampton, S. L. et al., KVD900 as a Single Dose, Rapid, Oral, Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmcodynamic results from a Phase 1 Single Asc… [cited by applicant]
Heifetz, A. et al., Fragment Molecular Orbital Method Applied to Lead Optimization of Novel Interleukin-2 Inducible T-Cell Kinase (ITK) Inhibitors, J. Med. Chem., 59(9):4352-4363 (2016). [cited by applicant]
International Search Report for PCT/US2019/021897 (Substituted Imidazopyridines as Inhibitors of Plasma Kallikrein and Uses Thereof, filed Mar. 12, 2019), issued by ISA/EPO, 6 pages (May 9, 2019). [cited by applicant]
International Search Report for PCT/US2020/051249 filed Sep. 17, 2020, 5 pages, (Nov. 23, 2020). [cited by applicant]
International Search Report for PCT/US2020/051293, filed Sep. 17, 2020, 5 pages, (Nov. 10, 2020). [cited by applicant]
International Search Report for PCT/US2022/020474, filed Mar. 16, 2022, 5 pages, (mailed May 31, 2022). [cited by applicant]
International Search Report for PCT/US2022/020479, filed Mar. 16, 2022, 4 pages, (mailed May 27, 2022). [cited by applicant]
International Search Report for PCT/US2022/020482, filed Mar. 16, 2022, 4 pages, (mailed May 31, 2022). [cited by applicant]
International Search Report for PCT/US2022/020491, filed Mar. 16, 2022, 6 pages, (mailed May 30, 2022). [cited by applicant]
International Search Report for PCT/US2022/020527, filed Mar. 16, 2022, 7 pages, (mailed Jun. 7, 2022). [cited by applicant]
Li, Z. et al., Diversity-oriented synthesis of β-lactams and γ-lactams by post-Ugi nucleophilic cyclization: Lewis acids as regioselective switch, European Journal of Organic Chemistry, 18: 3957-3962 (2015). [cited by applicant]
Longhurst, H. et al., Oral Plasma Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial, Presented at AAAAI 2019, … [cited by applicant]
Nirogi, R. et al., Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease, European Journal of Medicinal C… [cited by applicant]
Roatsch, M. et al., Substituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylases, Future Med. Chem., 8(13):1553-1571 (2016). [cited by applicant]
Registry Database Compound RN 1239205-88-9, 1 page, Aug. 26, 2010. [cited by applicant]
Busse, P. and Kaplan, A., Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade, J. Allergy Clin. Immunol. Pract., 10(3):716-722 (2022). [cited by applicant]